BTG upgrades guidance – again

BTG upgrades guidance – again

BTG's (BTG) shares seem to have found renewed momentum following a 12-month trough in July, and these half-year numbers – which included an FY2019 guidance upgrade for the company’s pharmaceuticals division – have inspired further confidence. The company has also made its final $73.3m (£56.9m) payment to settle its ongoing legal dispute with Wellstat Therapeutics, albeit sending free cash flow down by nearly two-thirds during the period.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now